Delivery of Cell, RNA and DNA Therapeutics | Surveying the Business and IP Landscape
The rapidly growing pipeline of promising cell and gene therapy candidates has created a growing focus on delivery technology that safely and effectively allows these therapies to reach their disease targets in humans. Merger and acquisition activity is heating up over companies with strong delivery technology for cell and gene therapy products, such as Catalent’s $1.2 billion purchase of Paragon, a leading viral vector development and manufacturing company. The successful launch of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines has further validated the future of therapeutics in these areas.
Foley partners Steve Maebius and Tianran Yan, Foley patent agent Jennie Zheng, and biotechnology investment analyst Shaun Mehra will address the key business and intellectual property considerations driving activity in this area, while providing insights into the latest trends impacting successful business and patent strategies.